This week, we'll review two influential breast cancer studies presented during the ASCO20 Virtual Scientific Program: MINDACT and HER2CLIMB."}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll review two influential breast cancer studies presented during the ASCO20 Virtual Scientific Program: MINDACT and HER2CLIMB.

This week, we'll review two influential breast cancer studies presented during the ASCO20 Virtual Scientific Program: MINDACT and HER2CLIMB."}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll review two influential breast cancer studies presented during the ASCO20 Virtual Scientific Program: MINDACT and HER2CLIMB.

This week, we'll review two influential breast cancer studies presented during the ASCO20 Virtual Scientific Program: MINDACT and HER2CLIMB."}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"&gt; This week, we'll review two influential breast cancer studies presented during the ASCO20 Virtual Scientific Program: MINDACT and HER2CLIMB.

Spotlight on Two Breast Cancer Studies From the ASCO20 Virtual Scientific Program

News and views from the world of clinical oncology and hematology.

Share Spotlight on Two Breast Cancer Studies From the ASCO20 Virtual Scientific Program

Sign up to save your podcasts

Spotlight on Two Breast Cancer Studies From the ASCO20 Virtual Scientific Program

Spotlight on Two Breast Cancer Studies From the ASCO20 Virtual Scientific Program